Ionis Education Group company information, Employees & Contact Information

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture Yahoo Finance

IONIS Education Group Launches a Research and Excellence Center in Generative AI Dedicated to Pedagogy and Education ActuIA

Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians Fierce Pharma

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome BioSpace

FDA approves Ionis’ treatment for a rare metabolic disorder Endpoints News

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) BioSpace

A 'pivotal moment': Ionis enters next phase of commercial evolution with Tryngolza's FDA approval Fierce Pharma

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Biogen

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema PR Newswire

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome BioSpace

Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials statnews.com

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome PR Newswire

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides BioSpace

Ionis announces positive donidalorsen late-stage clinical progress in HAE PR Newswire

Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema PR Newswire

Ionis reports second quarter 2025 financial results and highlights progress on key programs BioSpace

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease PR Newswire

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome PR Newswire

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema PR Newswire

Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting PR Newswire

Ionis reports first quarter 2025 financial results BioSpace

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results BioSpace

Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America PR Newswire

Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC Biogen

Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial PR Newswire

Ionis partners with Metagenomi to add gene editing to its broad technology platform PR Newswire

Oxford Properties Expands its San Diego Life Science Presence with Purchase and Lease Back of Ionis Campus PR Newswire

Ionis presents pivotal rare disease data, builds toward first solo launch: #ACC24 Endpoints News

With first MASH drug due for FDA nod, Ionis says me too with phase 2 data Fierce Biotech

AstraZeneca, Ionis' eplontersen shows sustained benefit on neuropathy impairment, QoL FirstWord Pharma

Ionis' lipid-lowering drug hits phase 3 goal, raising hopes in untapped rare disease market Fierce Biotech

Oxford breaks ground on 165,000 sq ft expansion of Ionis Pharmaceuticals Carlsbad campus Oxford Properties

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD ScienceDirect.com

CBRE Arranges $258.4 Million Sale and Leaseback of the 246,000 SF Ionis Pharmaceuticals’ Campus in San Diego County CBRE

ACC: Ionis' rare metabolic disorder drug slides from 100% efficacy, but FDA ambitions unchanged Fierce Biotech

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis PR Newswire

Ionis' antisense drug curbs HAE attacks in phase 2 Fierce Biotech

Ionis Pharmaceuticals Sells Carlsbad Campus to Global Firm for $258M, But Retains Use of Site Times of San Diego

Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga GuruFocus

Arrowhead chases Ionis in rare, genetic disease race BioWorld MedTech

Oxford Properties Breaks Ground on 165 KSF Life Science Expansion Commercial Search

Roche announces details of its 'pivotal' huntingtin-lowering study HDBuzz

Layoff Watch: Can Ionis Pharmaceuticals Inc. stock weather global recession - July 2025 PostEarnings & Stepwise Trade Signal Guides Trung tâm Dự báo KTTV quốc gia

FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS PR Newswire

Stanley Crooke on finally making sense out of antisense Chemical & Engineering News

Akcea and Ionis Gear Up for Second Attempt at Getting Waylivra FDA Approval BioSpace

Ionis, which has transformed medicine, undergoes its own transformation San Diego Union-Tribune

The top 10 best-paying places to work in biopharma Fierce Pharma

From Isis Pharma to Ionis San Diego Union-Tribune

Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright Defense World

JPMorgan Chase & Co. Upgrades Ionis Pharmaceuticals (NASDAQ:IONS) to “Overweight” Defense World

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of “Moderate Buy” by Analysts Defense World